NVIV Invivo Therapeutics Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVIV

Price (delayed)

$0.6601

Market cap

$2.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.29

Enterprise value

-$6.53M

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary ...

Highlights
The debt has plunged by 100% from the previous quarter and by 100% YoY
NVIV's quick ratio has soared by 64% QoQ
NVIV's equity is down by 23% since the previous quarter and by 12% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.invivotherapeutics.com
Peers: CTSO BSX

Key stats

What are the main financial stats of NVIV
Market
Shares outstanding
3.11M
Market cap
$2.05M
Enterprise value
-$6.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.23
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$9.18M
EBITDA
-$8.76M
Free cash flow
-$10.08M
Per share
EPS
-$3.29
Free cash flow per share
-$3.24
Book value per share
$2.87
Revenue per share
$0
TBVPS
$3.09
Balance sheet
Total assets
$9.58M
Total liabilities
$666,000
Debt
$0
Equity
$8.92M
Working capital
$8.86M
Liquidity
Debt to equity
0
Current ratio
14.3
Quick ratio
12.88
Net debt/EBITDA
0.98
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-65%
Return on equity
-75%
Return on invested capital
-728%
Return on capital employed
-102.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVIV stock price

How has the Invivo Therapeutics Holdings stock price performed over time
Intraday
-0.5%
1 week
-4.33%
1 month
-29.02%
1 year
-67%
YTD
-71.91%
QTD
-41.06%

Financial performance

How have Invivo Therapeutics Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.86M
Net income
-$9.33M
Gross margin
N/A
Net margin
N/A
NVIV's net income is up by 16% year-on-year
Invivo Therapeutics Holdings's operating income has increased by 11% YoY

Growth

What is Invivo Therapeutics Holdings's growth rate over time

Valuation

What is Invivo Therapeutics Holdings stock price valuation
P/E
N/A
P/B
0.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NVIV's EPS has surged by 58% year-on-year and by 25% since the previous quarter
NVIV's P/B is 67% below its 5-year quarterly average of 0.7 and 23% below its last 4 quarters average of 0.3
NVIV's equity is down by 23% since the previous quarter and by 12% year-on-year

Efficiency

How efficient is Invivo Therapeutics Holdings business performance
NVIV's return on invested capital is down by 18% since the previous quarter and by 16% year-on-year
Invivo Therapeutics Holdings's ROA has decreased by 6% from the previous quarter and by 2.7% YoY
NVIV's return on equity is up by 4% year-on-year

Dividends

What is NVIV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVIV.

Financial health

How did Invivo Therapeutics Holdings financials performed over time
The total liabilities has dropped by 80% year-on-year and by 62% since the previous quarter
NVIV's quick ratio has soared by 64% QoQ
The debt is 100% less than the equity
The debt has plunged by 100% from the previous quarter and by 100% YoY
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.